Complex Lung Disease News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference
-Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-
-Post-hoc analysis from ARIKAYCE® (amikacin liposome inhalation suspension) clinical trials supports favorable benefit and safety profile, with a low number needed to treat (NNT) and high number needed to harm (NNH)-
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP) at the virtual America ....

United States , New Jersey , Treprostinil Palmitil , Pharma Gmb , Mandy Fahey , Martina Flammer , Eleanor Barisser , Drug Administration , Prnewswire Insmed Incorporated Nasdaq , Company Annual Report On Form , Exchange Commission , Corporate Communications , Insmed Incorporated , Regional Poison Control Center , International Conference , American Thoracic Society , Chief Medical Officer , Mortality Associated , Nontuberculous Mycobacterial Lung Disease Among , Chronic Obstructive Pulmonary , Oral Title , Amikacin Liposome Inhalation Suspension , Refractory Mycobacterium , Complex Lung Disease , Number Needed , Poster Title ,